Josh has worked closely with NEA since his time as an EIR back in 1995 and joined full-time as a General Partner on NEA’s healthcare team leading our medtech/healthtech practice in 2015. Josh is also the Founder and Executive Chairman of ExploraMed, a medical device incubator that has created 8 companies over the past 20 years.

Notable transactions from the ExploraMed portfolio include Acclarent, acquired by J&J in 2009. EndoMatrix, acquired by C.R. Bard in 1997, TransVascular, acquired by Medtronic in 2003 and Neotract acquired by Teleflex in 2017. On-going ExploraMed/NEA ventures include Moximed, Willow, NC8 and ExploraMed V.

In addition to his role at NEA, Josh serves on the faculty of the Stanford University Medical School as an Adjunct Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh currently serves on the board of directors for Foundry Therapeutics 1, Lungpacer, NC8, Magenta Medical, Vesper Medical, DOTS Technology Corp., ExploraMed, Intrinsic Therapeutics, Moximed, SetPoint Medical, Willow and Coravin.

Josh holds over 300 patents and patent applications for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, an MD from the NYU School of Medicine, and a bachelor’s degree in Mechanical Engineering from MIT.